Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7723062 | 0.82 | ALDH1A1 (0.46) | ALDH1A1NAMPTSLC2A1CYP19A1HSD17B10 | |
| SCHEMBL7724199 | 0.81 | ALDH1A1 (0.44) | ALDH1A1NAMPTSLC2A1CYP19A1HSD17B10 | |
| SCHEMBL1677833 | 0.80 | EPHX1 (0.51) | ALDH1A1NAMPTCYP19A1EPHX1MAPT | |
| SCHEMBL1678521 | 0.74 | EPHX1 (0.46) | ALDH1A1NAMPTEPHX1MAPT | |
| SCHEMBL7729401 | 0.73 | HSD17B10 (0.48) | ALDH1A1HSD17B10EPHX1MAPTMAPK1 | |
| SCHEMBL7729364 | 0.72 | KDM4E (0.38) | NAMPTHSD17B10 | |
| SCHEMBL7723097 | 0.72 | HSD17B10 (0.42) | ALDH1A1NAMPTHSD17B10EPHX1MAPT | |
| SCHEMBL1677553 | 0.72 | ALDH1A1 (0.43) | ALDH1A1NAMPTHSD17B10EPHX1MAPT | |
| SCHEMBL7723885 | 0.72 | HSD17B10 (0.41) | ALDH1A1NAMPTHSD17B10EPHX1MAPT | |
| Hydrochloric Acid SCHEMBL1678455 | 0.72 | EPHX1 (0.46) | ALDH1A1NAMPTEPHX1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420398-B2 | FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-11-15 | — | — | US | disclosed |
| EP-1103543-A1 | NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | TNF, UACA, HRH4 | ALDH1A1 988/4885NAMPT 3320/4885SLC2A1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.